Asset profile
tocilizumab · Actemra / RoActemra
Monoclonal antibody
Approvedregulatory verdict
Evidence outlook
Approved: Rheumatoid Arthritis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 3 direct rivals (same mechanism and indication), 0 same-class, 57 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Tocilizumab (Actemra / RoActemra): this drug | Approved | Monoclonal antibody | IL-6 receptor, IL-6R antagonist | ||
| CT-P47 (tocilizumab) (Avtozma) | Approved | Monoclonal antibody | IL-6R antagonist | ||
| Sarilumab | Approved | Monoclonal antibody | IL-6 receptor | ||
| Levilimab | Phase 3 | Monoclonal antibody | IL-6 receptor | ||
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Ryvk (Simlandi) | Approved | — | TNF-alpha | ||
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | ||
| Anakinra (r-metHuIL-1ra) | Approved | Protein / enzyme therapeutic | Interleukin-1 receptor (IL-1R), Interleukin-1 receptor type 1 (IL-1R1) | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | ||
| CT-P13 (Inflectra / Remsima) | Approved | Monoclonal antibody | TNF-alpha | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Etanercept (Enbrel) | Approved | Protein / enzyme therapeutic | TNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha) | ||
| Golimumab (Simponi) | Approved | Monoclonal antibody | TNF-alpha |
…and 45 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(76 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (8)
October 2026 (2)
November 2026 (2)
December 2026 (4)
Phase 1/2Lung Cancer, Nonsmall CellRecruiting
Est. primary completion 2026-12 · NCT04691817 · CT.gov ↗
What to watch
Phase 2Myeloma, Lymphoma, LeukemiaRecruiting
Est. primary completion 2026-12 · NCT06430736 · CT.gov ↗
What to watch
Phase 2Sickle Cell Disease, Acute Chest SyndromeRecruiting
Est. primary completion 2026-12 · NCT05640271 · CT.gov ↗
What to watch
Phase 2Sars-CoV2Active not recruiting
Est. primary completion 2026-12-01 · NCT04363853 · CT.gov ↗
What to watch
2027 (30)
January 2027 (3)
Phase 3Giant Cell ArteritisActive not recruiting
Est. primary completion 2027-01 · NCT03892785 · CT.gov ↗
What to watch
Early phase / not applicableKidney Transplant RejectionRecruiting
Est. primary completion 2027-01-01 · NCT07006532 · CT.gov ↗
What to watch
Phase 1Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-01-09 · NCT04616248 · CT.gov ↗
What to watch
February 2027 (2)
March 2027 (2)
April 2027 (4)
Phase 3Sickle Cell Disease, Acute Chest SyndromeRecruiting
Est. primary completion 2027-04 · NCT06818266 · CT.gov ↗
What to watch
Phase 3Ischemic StrokeRecruiting
Est. primary completion 2027-04-20 · NCT07509645 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2027-04-30 · NCT03448042 · CT.gov ↗
What to watch
Phase 2Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate CancerRecruiting
Est. primary completion 2027-04-30 · NCT03821246 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1/2Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer …Recruiting
Est. primary completion 2027-05-10 · NCT03564340 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Giant Cell Arteritis (GCA)Recruiting
Est. primary completion 2027-06-11 · NCT07108387 · CT.gov ↗
What to watch
July 2027 (5)
Phase 2Relapsing PolychondritisRecruiting
Est. primary completion 2027-07 · NCT06941376 · CT.gov ↗
What to watch
Phase 1/2Advanced Liver CancersActive not recruiting
Est. primary completion 2027-07-30 · NCT04524871 · CT.gov ↗
What to watch
Phase 1Relapsed or Refractory Multiple MyelomaRecruiting
Est. primary completion 2027-07-31 · NCT05927571 · CT.gov ↗
What to watch
Phase 2Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck CancerActive not recruiting
Est. primary completion 2027-07-31 · NCT03708224 · CT.gov ↗
What to watch
Phase 2Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-07-31 · NCT05207670 · CT.gov ↗
What to watch
August 2027 (3)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-08 · NCT05972135 · CT.gov ↗
What to watch
Phase 1CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma …Active not recruiting
Est. primary completion 2027-08-01 · NCT04007029 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2027-09-01 · NCT07774247 · CT.gov ↗
What to watch
October 2027 (1)
Phase 4Relapsed/Refractory Multiple Myeloma (RRMM)Recruiting
Est. primary completion 2027-10-11 · NCT07609940 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1Systemic Lupus ErythematosusActive not recruiting
Est. primary completion 2027-11-30 · NCT05835986 · CT.gov ↗
What to watch
December 2027 (6)
Phase 2Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous CraniopharyngiomaRecruiting
Est. primary completion 2027-12 · NCT05233397 · CT.gov ↗
What to watch
Phase 2Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer, ER Positive, HER2 Negative Breast CancerRecruiting
Est. primary completion 2027-12 · NCT05846789 · CT.gov ↗
What to watch
Phase 3Giant Cell ArteritisActive not recruiting
Est. primary completion 2027-12 · NCT06037460 · CT.gov ↗
What to watch
Phase 3Systemic Sclerosis, Interstitial Lung DiseaseRecruiting
Est. primary completion 2027-12-30 · NCT06297096 · CT.gov ↗
What to watch
Phase 2Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma …Active not recruiting
Est. primary completion 2027-12-31 · NCT04940299 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT07589634 · CT.gov ↗
What to watch
2028 (17)
January 2028 (2)
March 2028 (1)
Phase 3Diffuse Large B-cell LymphomaActive not recruiting
Est. primary completion 2028-03-31 · NCT04408638 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Antibody-mediated RejectionActive not recruiting
Est. primary completion 2028-06 · NCT04561986 · CT.gov ↗
What to watch
July 2028 (4)
Phase 2Treatment-Resistant Major Depressive DisorderNot yet recruiting
Est. primary completion 2028-07-01 · NCT07052058 · CT.gov ↗
What to watch
Phase 1Leukemia Acute Myeloid - AMLNot yet recruiting
Est. primary completion 2028-07-10 · NCT07392814 · CT.gov ↗
What to watch
Phase 1Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral IschemiaRecruiting
Est. primary completion 2028-07-30 · NCT06863480 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2028-07-31 · NCT05583617 · CT.gov ↗
What to watch
August 2028 (2)
September 2028 (2)
October 2028 (2)
Phase 3Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated VasculitisRecruiting
Est. primary completion 2028-10 · NCT04871191 · CT.gov ↗
What to watch
Phase 1/2Granulomatous Lobular Mastitis, Granulomatous MastitisNot yet recruiting
Est. primary completion 2028-10-30 · NCT07595900 · CT.gov ↗
What to watch
November 2028 (2)
December 2028 (1)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-12-21 · NCT04910568 · CT.gov ↗
What to watch
2029 (9)
January 2029 (1)
Phase 2Lung TransplantRecruiting
Est. primary completion 2029-01-08 · NCT06033196 · CT.gov ↗
What to watch
March 2029 (2)
April 2029 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-04-13 · NCT07825064 · CT.gov ↗
What to watch
May 2029 (1)
Phase 3Polyarticular Course Juvenile Idiopathic Arthritis (JIA)Recruiting
Est. primary completion 2029-05-30 · NCT06654882 · CT.gov ↗
What to watch
July 2029 (1)
Phase 4Rheumatoid ArthritisNot yet recruiting
Est. primary completion 2029-07-31 · NCT07643038 · CT.gov ↗
What to watch
August 2029 (1)
Phase 1Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2029-08-05 · NCT05169515 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Multiple Myeloma (MM), Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Multiple MyelomaRecruiting
Est. primary completion 2029-10 · NCT07637578 · CT.gov ↗
What to watch
November 2029 (1)
Phase 1/2Mature B-Cell Non-Hodgkin LymphomaRecruiting
Est. primary completion 2029-11-30 · NCT05533775 · CT.gov ↗
What to watch
2030 (6)
March 2030 (3)
Phase 1CalciphylaxisNot yet recruiting
Est. primary completion 2030-03 · NCT07708038 · CT.gov ↗
What to watch
Phase 1Lupus Erythematosus, SystemicRecruiting
Est. primary completion 2030-03-29 · NCT07629583 · CT.gov ↗
What to watch
Phase 3New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)Not yet recruiting
Est. primary completion 2030-03-31 · NCT07281027 · CT.gov ↗
What to watch
August 2030 (1)
Phase 1AQP4+ NMOSDNot yet recruiting
Est. primary completion 2030-08-01 · NCT07573332 · CT.gov ↗
What to watch
2031 (2)
2032 (1)
April 2032 (1)
Phase 2Mantle Cell Lymphoma, Mantle Cell Lymphoma RefractoryRecruiting
Est. primary completion 2032-04 · NCT05833763 · CT.gov ↗
What to watch
2033 (2)
October 2033 (1)
Phase 2/3B-cell Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2033-10-18 · NCT07570173 · CT.gov ↗
What to watch
November 2033 (1)
Phase 2Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic MalignanciesNot yet recruiting
Est. primary completion 2033-11-16 · NCT07709000 · CT.gov ↗
What to watch
2042 (1)
July 2042 (1)
Phase 1Cholangiocarcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2042-07 · NCT07594067 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.